Top Markets
Coin of the day
Vectus Biosystems Limited Vectus Biosystems Limited

Vectus Biosystems Limited

VBS
Rank in Stocks #33746
Vectus Biosystems Limited, an Australian medical research and development firm,... Vectus Biosystems Limited, an Australian medical research and development firm, specializes in devising therapies for fibrotic conditions and hypertension. Its pharmaceutical pipeline addresses ailments affecting the heart, kidneys, liver, and lungs. The company's leading experimental drug, VB0004, aims to counter the degradation of functional tissue resulting from fibrosis, scarring, and elevated blood pressure. Furthermore, Vectus intends to advance treatments for hepatic fibrotic diseases, such as non-alcoholic steatohepatitis, and various pulmonary fibrotic disorders. Beyond its therapeutic endeavors, the company also provides AccuCal and RealCount software, tools engineered to enhance the swiftness and precision of DNA and RNA quantification in laboratory settings. Established in 2005, Vectus Biosystems is headquartered in Rosebery, Australia.
Share Price
$0.11284557
Market Cap
$6.98M
Change (1 day)
0.00%
Change (1 year)
162.85%
Country
AU
Trade Vectus Biosystems Limited (VBS)

Category

P/S ratio for Vectus Biosystems Limited (VBS)
P/S ratio as of 2026 TTM: 0
According to Vectus Biosystems Limited latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for Vectus Biosystems Limited from 2026 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
Not enough data for the provided dates.
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
10.17 -
US
10.13 -
NL
- -
CH
- -
KR
4.74 -
BE